Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InflaRx ( (IFRX) ) just unveiled an update.
On July 11, 2025, InflaRx N.V. announced that it received a notice from Nasdaq indicating that its ordinary shares had closed below the minimum $1.00 per share requirement for the past 30 consecutive business days. The company has until January 7, 2026, to regain compliance, with a potential extension until July 6, 2026, if necessary. This notice does not immediately affect the listing or trading of InflaRx’s shares, and the company is exploring options to meet the compliance requirements.
The most recent analyst rating on (IFRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
InflaRx’s overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows being the primary concerns. Technical analysis provides a neutral outlook, while poor valuation metrics add further downside risk. The absence of earnings call data and corporate events does not alter the fundamentally weak position.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system. The company utilizes its proprietary anti-C5a and anti-C5a receptor technologies to create highly potent inhibitors of the complement activation factor C5a and its receptor. InflaRx’s key products include vilobelimab, an intravenously delivered anti-C5a monoclonal antibody, and INF904, an orally administered small molecule inhibitor.
Average Trading Volume: 498,505
Technical Sentiment Signal: Sell
Current Market Cap: $59.08M
For detailed information about IFRX stock, go to TipRanks’ Stock Analysis page.